pre-seed
Stage
1
Investors
About
CGenetix develops non-invasive liquid biopsy technologies utilizing epigenetics-based analysis and digital PCR testing to monitor organ damage and transplant rejection in kidney and lung transplant patients.
Explore CGenetix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.